List of Excipients in Branded Drug RYPLAZIM

RYPLAZIM Excipient Strategy and Commercial Opportunities

Last updated: August 26, 2026

RYPLAZIM is a plasma-derived human plasminogen replacement therapy approved for type 1 plasminogen deficiency. Its commercial opportunity is concentrated in high-value specialty biologics, sterile lyophilized formulation, reconstitution systems, cold-chain logistics, and manufacturing support rather than conventional generic excipient substitution. The product’s relatively simple presentation creates opportunities to improve administration, stability, packaging, and supply reliability without changing the active protein formulation.

What is RYPLAZIM and how is it administered?

RYPLAZIM is plasminogen human, a purified protein derived from pooled human plasma. The FDA approved it on May 4, 2021, under Biologics License Application 761179 for the treatment of patients with type 1 plasminogen deficiency. The approved regimen is 6.6 mg/kg administered intravenously every two weeks.[1]

Product attribute	RYPLAZIM profile
Active ingredient	Plasminogen human
Therapeutic class	Plasma-derived protein replacement
Indication	Type 1 plasminogen deficiency
FDA approval	May 4, 2021
BLA	761179
Dosage form	Lyophilized powder for solution
Administration	Intravenous infusion
Dose	6.6 mg/kg every two weeks
Vial strength	Approximately 68.8 mg plasminogen
Reconstitution	Sterile Water for Injection
Preservatives	None identified in U.S. prescribing information
Applicant identified in FDA labeling	Liminal BioSciences Inc.

The treatment is chronic for many patients. At a body weight of 70 kg, one dose is approximately 462 mg, requiring about seven 68.8 mg vials before accounting for dose rounding and vial overfill. At 26 treatment cycles per year, this equals roughly 182 vials annually.

What excipients are used in RYPLAZIM?

The U.S. prescribing information describes RYPLAZIM as a sterile, lyophilized preparation of human plasminogen reconstituted with Sterile Water for Injection. The label states that the product contains no preservatives.[1]

Public labeling does not present RYPLAZIM as a conventional small-molecule formulation with a broad inactive-ingredient profile. That distinction matters commercially. The principal formulation value lies in preserving protein activity, controlling aggregation, supporting lyophilization, and maintaining sterility rather than in replacing a tablet filler, coating agent, or solubilizer.

Excipient strategy implications

A low-excipient or minimally disclosed formulation can reduce certain compatibility risks, but it places greater weight on:

• Protein stabilization during freeze-drying and storage
• Control of aggregation and particle formation
• Reconstitution time and completeness
• Container-closure integrity
• Infusion-line compatibility
• Recovery of the full labeled dose from each vial
• Stability after reconstitution
• Lot-to-lot consistency for a plasma-derived protein

Potential formulation components in a future or improved presentation could include buffers, tonicity agents, amino-acid stabilizers, surfactants, or bulking agents. Any such change would require analytical and clinical comparability work because the active ingredient is a complex plasma-derived protein rather than a chemically defined molecule.

What excipient opportunities exist for RYPLAZIM?

The strongest commercial opportunities are adjacent to the current product rather than direct replacement of its core formulation.

1. Lyophilization excipients and cycle optimization

Suppliers of formulation-grade stabilizers, bulking agents, and cryoprotectants may support process improvements. Potential technical targets include:

• Reduced cake collapse
• Shorter primary drying cycles
• Improved residual-moisture control
• Lower aggregation after reconstitution
• Better stability during temperature excursions
• Higher recovery of active plasminogen

For a rare-disease product, manufacturing yield has an outsized economic effect because annual patient demand is low but the product has high value per treatment course. A small improvement in recovery can reduce plasma consumption, batch failures, and vial shortages.

The commercial barrier is that a formulation change may affect potency, immunogenicity, degradation products, and the validated manufacturing process. The opportunity is therefore strongest for excipients already used in licensed biologics, where regulatory precedent is established.

2. Reconstitution and administration systems

RYPLAZIM is supplied as a lyophilized powder requiring reconstitution. This creates opportunities for:

• Vial-adapter systems
• Needle-free transfer devices
• Closed-system reconstitution components
• Prefilled diluent presentations
• Dual-chamber systems
• Low-hold-up-volume transfer devices
• Infusion sets designed for protein biologics

A 70 kg patient may require approximately seven vials per administration. At that volume, reducing transfer loss and preparation time can have meaningful value. A device that improves dose recovery or simplifies home infusion may be commercially more attractive than a new excipient.

3. Container-closure systems

Primary packaging is a significant development area for plasma-derived proteins. Opportunities include:

• Low-binding glass vials
• Silicone-controlled syringe or transfer components
• Improved elastomer formulations
• Better moisture barriers
• Tamper-evident packaging
• Integrated vial and diluent kits

Container components must be assessed for protein adsorption, extractables, leachables, particulate generation, and closure integrity. A packaging change may preserve the approved formulation while improving shelf life or reducing administration losses.

4. Stability and cold-chain support

Suppliers can create value through:

• Validated temperature-monitoring systems
• Insulated shipping configurations
• Excursion-management protocols
• Secondary packaging that limits light or thermal exposure
• Stability-indicating analytical methods
• Reconstitution-time and in-use stability studies

For an orphan biologic, reducing product loss during distribution can produce more value than pursuing an unproven excipient innovation. A failed shipment represents a large percentage of annual demand for a small patient population and can interrupt chronic replacement therapy.

5. Manufacturing and plasma-processing support

RYPLAZIM is plasma-derived, so the supply chain includes plasma collection, donor screening, viral testing, fractionation, purification, and viral clearance. Commercial opportunities include:

• Plasma pool management
• Single-use process equipment
• Virus filtration
• Chromatography resins
• Protein recovery systems
• Sterile filtration
• Aseptic filling
• Lyophilization capacity
• Analytical testing for identity, purity, potency, and aggregates

These activities may offer stronger barriers to entry than the excipient itself. A supplier with validated processes for plasma-derived proteins can become embedded in the manufacturing network and may be difficult to replace without comparability and process-validation work.

How does RYPLAZIM’s formulation compare with conventional biologics?

RYPLAZIM differs from many monoclonal antibodies and recombinant proteins because it is a plasma-derived replacement protein with a lyophilized presentation and a relatively small patient population.

Attribute	RYPLAZIM	Typical recombinant biologic	Commercial implication
Source	Human plasma	Recombinant cell culture	Plasma supply and viral safety are central
Presentation	Lyophilized vial	Liquid or lyophilized	Reconstitution systems have higher value
Dose frequency	Every two weeks	Product-specific	Chronic recurring demand
Patient population	Ultra-rare	Often larger	High price per patient, limited volume
Formulation priority	Protein recovery and stability	Stability, viscosity, aggregation	Low-dose losses can matter materially
Substitution route	Biosimilar pathway	Biosimilar pathway	No conventional ANDA generic
Packaging sensitivity	High	High	Container and transfer-device opportunities

What regulatory protections and exclusivity apply to RYPLAZIM?

RYPLAZIM is regulated as a biologic, not as a conventional small-molecule drug. It therefore does not use the standard Orange Book generic-substitution framework.

FDA exclusivity timeline

Protection	Relevant date	Commercial effect
FDA approval	May 4, 2021	Reference product licensed
Orphan-drug exclusivity	Expected through May 4, 2028	FDA generally cannot approve the same drug for the same indication during the seven-year period
Biologic data exclusivity	Expected through May 4, 2033	Biosimilar approval generally cannot occur before 12 years after first licensure
Patent protection	Patent-specific	Must be assessed from issued claims and expiration data

The seven-year orphan period and the 12-year biologic exclusivity period operate differently. Orphan exclusivity is indication-specific and concerns the same drug for the protected disease. Biologic data exclusivity delays biosimilar approval more broadly under the Public Health Service Act. FDA’s Purple Book, not the Orange Book, is the relevant reference for biological products and biosimilar information.[2,3]

What is the Orange Book and Purple Book status of RYPLAZIM?

RYPLAZIM is not expected to have a conventional Orange Book listing because it is licensed under a BLA. FDA’s Purple Book identifies licensed biological products and relevant reference-product information. The absence of an Orange Book listing does not mean that the product lacks patent protection.

Patent issues may involve:

• Plasminogen purification
• Viral inactivation and clearance
• Formulation and lyophilization
• Dosing in type 1 plasminogen deficiency
• Treatment of ligneous conjunctivitis or other disease manifestations
• Manufacturing controls
• Container-closure or delivery systems

Patent claims must be reviewed separately from FDA exclusivity. A formulation patent may expire before biologic data exclusivity, while a later-issued method-of-use or manufacturing patent could extend litigation risk beyond the earliest composition claims.

When does RYPLAZIM lose exclusivity?

The key statutory dates are 2028 for orphan-drug exclusivity and 2033 for the 12-year biologic reference-product exclusivity period, assuming no relevant statutory adjustment.

A biosimilar developer could pursue development before 2033, but FDA approval timing is constrained by the biologic exclusivity framework. Patent litigation, settlement terms, pediatric exclusivity, regulatory amendments, and the scope of the biosimilar application could affect actual market entry.

Unlike a small molecule, RYPLAZIM is unlikely to face a conventional ANDA Paragraph IV challenge. A competitor would generally use the biosimilar pathway and the patent-disclosure and litigation procedures associated with the Biologics Price Competition and Innovation Act.

What generic or biosimilar entry risks exist?

Near-term substitution risk is limited by three factors:

1. RYPLAZIM is an ultra-rare biologic.
2. The product has a complex plasma-derived manufacturing process.
3. The 12-year reference-product exclusivity period generally extends beyond the orphan period.

The most credible long-term competitor would be a biosimilar or interchangeable biological product supported by analytical comparability, clinical pharmacology, immunogenicity, and manufacturing data. A biosimilar developer would also need reliable access to a comparable plasminogen source or a sufficiently similar manufacturing platform.

Biosimilar barriers

Key development barriers include:

• Limited patient numbers for clinical studies
• Difficulty recruiting patients with congenital plasminogen deficiency
• Complex characterization of a plasma-derived protein
• Batch-to-batch variability
• Need to demonstrate comparable potency and purity
• Viral-safety validation
• Plasma supply and donor-network requirements
• High cost of establishing commercial-scale sterile manufacturing

These barriers reduce the attractiveness of a low-price, high-volume generic strategy. A future entrant would more likely pursue a premium specialty-biologic model.

What commercial opportunities exist beyond excipients?

The highest-value opportunities are likely to be platform and service businesses.

Specialty manufacturing

Contract manufacturers with experience in plasma-derived proteins, aseptic filling, and lyophilization can compete for supply contracts. Capacity is strategically valuable because a sponsor may not want to qualify a new manufacturing site for a low-volume orphan product unless the site offers meaningful resilience or cost reductions.

Home-infusion enablement

A home-infusion package could improve treatment convenience through:

• Simplified reconstitution
• Fewer preparation steps
• Reduced infusion time
• Training materials
• Remote adherence monitoring
• Pharmacy and nursing coordination

Any such system must remain compatible with the approved route, dose, storage conditions, and product labeling unless supported by a regulatory supplement.

Diagnostic and patient-identification services

Type 1 plasminogen deficiency is rare and may be underdiagnosed. Commercial opportunities include:

• Plasminogen activity assays
• Genetic testing
• Referral networks
• Disease registries
• Treatment-monitoring services
• Specialty pharmacy case management

These services can expand diagnosis and treatment capture without changing the medicine itself.

Regional distribution and licensing

Because the patient population is geographically dispersed, commercial partners with rare-disease infrastructure may add value through:

• Country-specific regulatory submissions
• Named-patient or early-access programs
• Specialty pharmacy distribution
• Cold-chain logistics
• Reimbursement support
• Clinical-center relationships

Geographic expansion depends on local biologic regulations, plasma-derived product requirements, reimbursement, and the availability of diagnostic testing. The United States remains the primary reference market because of the 2021 FDA approval, but European and other-market opportunities would require separate regulatory and commercial assessment.

How strong is the RYPLAZIM commercial and IP position?

RYPLAZIM has a strong regulatory position through orphan designation and biologic exclusivity, but its commercial scale is constrained by the underlying disease prevalence and the need for recurring intravenous treatment.

Factor	Assessment
Regulatory exclusivity	Strong through orphan and biologic exclusivity periods
Patent visibility	Requires claim-level review; not captured through a conventional Orange Book listing
Manufacturing barrier	High because of plasma sourcing and protein purification
Formulation barrier	Moderate to high because of protein stability and lyophilization requirements
Biosimilar risk before 2033	Limited by biologic exclusivity
Biosimilar risk after 2033	Technically possible but difficult
Excipient substitution opportunity	Limited unless tied to a reformulation or manufacturing improvement
Device opportunity	Meaningful because of multi-vial reconstitution
Revenue exposure	High value per patient, low aggregate volume
Supply-chain opportunity	Strong for validated plasma, fill-finish, and cold-chain providers

Key Takeaways

• RYPLAZIM is a lyophilized, plasma-derived human plasminogen product approved in 2021 for type 1 plasminogen deficiency.
• The product’s public U.S. labeling emphasizes the active protein, sterile lyophilized presentation, Sterile Water for Injection reconstitution, and absence of preservatives.
• The best excipient opportunities involve protein stabilization, lyophilization performance, container compatibility, and dose recovery.
• Reconstitution devices and integrated diluent systems may offer greater commercial value than a new excipient.
• FDA orphan exclusivity is expected to run through May 2028, while biologic reference-product exclusivity is expected to run through May 2033.
• RYPLAZIM is subject to the biologic and biosimilar framework, not a conventional ANDA and Orange Book Paragraph IV process.
• Plasma sourcing, viral safety, purification, aseptic filling, and lyophilization create substantial manufacturing barriers.
• Revenue is likely to be concentrated in a small number of chronic patients requiring high-value recurring treatment.
• Patent protection must be analyzed separately from FDA exclusivity and should include formulation, dosing, treatment-method, and manufacturing claims.

FAQs About RYPLAZIM Excipient and Commercial Strategy

Can RYPLAZIM be reformulated as a liquid product?

A liquid reformulation is technically possible but would require extensive stability, aggregation, potency, container-closure, and regulatory comparability work. The lyophilized format likely reflects the stability requirements of the plasma-derived protein.

Is RYPLAZIM eligible for an interchangeable biosimilar?

Potentially, but an interchangeable designation would require satisfying FDA’s biosimilar and interchangeability standards. The complexity of plasma-derived plasminogen and the limited patient population would make the development program demanding.

Are excipient patents likely to block RYPLAZIM competition?

They could, but blocking strength depends on issued claims, expiration dates, prosecution history, and whether the claims cover the commercial formulation. FDA exclusivity and patent enforceability are separate issues.

What is the largest technical opportunity in RYPLAZIM packaging?

The largest opportunity is likely a low-loss, closed reconstitution and transfer system that reduces preparation time, protein adsorption, particulate risk, and residual drug left in multiple vials.

Can a generic manufacturer use an ANDA to copy RYPLAZIM?

No conventional ANDA route is expected because RYPLAZIM is licensed as a biologic. A competing product would generally require a biosimilar application under the Public Health Service Act.

References

1. U.S. Food and Drug Administration. (2021). RYPLAZIM (plasminogen human) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.

3. U.S. Food and Drug Administration. (2020). Licensure of reference products and exclusivity under the Biologics Price Competition and Innovation Act. FDA.

4. U.S. Food and Drug Administration. (2021). RYPLAZIM approval letter, BLA 761179. FDA.

5. U.S. Food and Drug Administration. (2023). Biosimilar and interchangeable biosimilar biological products: Questions and answers. FDA.